Breaking News

The company had to halt and later restart billing for its cancer risk assessment tests as it transitioned to a new billing process.

The study aims to understand the willingness of individuals with a clinical diagnosis of familial hypercholesterolemia and their family members to undergo confirmatory genetic testing.

The assay will use Genomic Vision technology and be used to study the role of telomere length in complex diseases.

Excluding the impact of a one-time conversion from cash-based to accrual-based revenue recognition in 2017, year-over-year revenues were essentially flat.

As the firm continues to move toward commercialization of its test, its loss dropped to $3.8 million, or $.12 per share, from $4.7 million, $.16 per share, in the same period last year.

The kit, designed to rapidly detect 16 beta-lactam and carbapenem-resistant pathogen targets, was CE marked last month.

The startup plans to harness single-cell genomics and computational analysis to discover therapies for autoimmune disease and cancer.

Researchers from the molecular diagnostics firm said their screen could identify a range of variant types to boost the identification of at-risk couples.

The financing round was led by Triventures, and included Inimiti Capital and Glilot Capital Partners.

Researchers described diet-related patterns of gut microbial diversity, microbiome ties to psychiatric disease, and more.

Malaysia-based ScienceVision has agreed to commercialize and distribute the PierianDx Clinical Genomics Workspace platform in Southeast Asian countries.

BioClin is developing a monoclonal antibody-based treatment for relapsed/refractory metastatic urothelial carcinoma with FGFR3 molecular alterations.

The award will go toward the development of MicrobeDx's technology for detecting the presence of bacteria in clinical urine specimens and to which antibiotics they are susceptible.

The test for resistance genes from carbapenemase-producing Gram-negative bacteria can now be used on perirectal swabs and pure colonies.

The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.

George Church's Nebula is teaming with Hong Kong startup Longenesis to create a secure platform for individuals and biobanks to sell access to their genomes.

Illumina said the acquisition will help enable a standardized process for sequencing and analysis and speed up the time it take to get a result.

The increase was drive by revenue growth in Cancer Genetics' discovery services unit, which included the impact of recently acquired CRO VivoPharm.

Unicancer will provide patients with centralized laboratory testing performed by Agendia, and also adopt the company's NGS kits for decentralized testing.

The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.

The firm provided full-year 2018 revenue and adjusted earnings guidance that fell below Wall Street's expectations.

Researchers analyzed HERBY trial data to uncover a subgroup of patients with MAPK pathway alterations who had increased overall survival.

A multi-region analysis of colorectal cancers suggests samples from opposite sides of a tumor can help trace early, invasiveness-related tumor characteristics.

The company said the disposal of these two businesses is part of a strategy to focus entirely on the molecular diagnostics market.

PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.

Pages

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.